Biotech insiders cheer IPO comeback after long 'winter' for going public

The biopharma industry racked up two more IPOs this week, with the monster deal for pharma services firm Quintiles ($Q) and public debut of MS drug developer Receptos ($RCPT). And more than two dozen life sciences companies, the Boston Globe reports, could go public this year--the biggest wave since 2007. The recession has put a damper on IPOs, but upbeat financial markets could mean that more companies might soon go public. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.